IOVA IOVANCE BIOTHERAPEUTICS, INC.

CIK 0001425205 50 ready 8-Ks latest July 2, 2026, 5:01 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing July 2, 2026, 5:01 PM ET

Top materiality 0.95

Event mix other_material ×24 · earnings ×12 · regulatory ×7

Sentiment 23 pos · 6 neg · 21 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for IOVA

Highest-materiality recent filing

Iovance receives FDA accelerated approval for AMTAGVI (lifileucel) in advanced melanoma

February 20, 2024, 6:59 PM ET other material materiality 0.95 positive item 2.02 item 8.01 item 9.01

AMTAGVI is first FDA-approved T cell therapy for a solid tumor cancer, indicated for advanced melanoma after anti-PD-1 and BRAF/MEK therapy.
Pivotal cohort (n=73) showed 31.5% objective response rate; median duration of response not reached at 18.6 months follow-up.

Read filing →

July 2, 2026, 5:01 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Iovance updates corporate presentation; guides FY26 revenue $350M-$370M, Q2 $86M-$88M

Q2 2026 revenue guidance of $86M-$88M; FY26 revenue guidance $350M-$370M; ~45% YoY quarterly growth.
June 10, 2026, 5:01 PM ET regulatory materiality 0.65 positive item 5.07 item 8.01 item 9.01

Iovance's Amtagvi granted TGA approval in Australia for advanced melanoma

Therapeutic Goods Administration of Australia approved Amtagvi for previously treated advanced melanoma.
May 7, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×3

Iovance Q1 revenue $71M (+45% YoY); guides FY26 $350-370M; endometrial cancer 40% cORR

Total product revenue ~$71M in Q1 2026, up 45% YoY; U.S. Amtagvi revenue ~$60M, Proleukin ~$11M.
February 24, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

Iovance Q4 product revenue $87M (30% QoQ), FY2025 $264M; FDA Fast Track for NSCLC

Q4 product revenue ~$87M, up ~30% QoQ; FY2025 total $264M, within $250-300M guidance.
January 9, 2026, 6:59 PM ET other material materiality 0.65 neutral item 8.01 item 9.01

Iovance reaffirms FY2025 revenue guidance of $250-300M; cash $307M as of Q3

Expects to achieve previously disclosed FY2025 revenue guidance of $250-300M in first full year of Amtagvi sales.
November 6, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Iovance Q3 revenue $68M (+13% QoQ), margin 43%; lifileucel NSCLC data durable

Q3 2025 product revenue ~$68M, up 13% sequentially; gross margin 43% on ~$39M cost of sales.
August 22, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

Iovance Biotherapeutics enters $350M ATM equity offering agreement with Jefferies

Agreement with Jefferies LLC to sell up to $350M of common stock in at-the-market offerings.
August 19, 2025, 7:59 PM ET regulatory materiality 0.70 positive item 8.01 item 9.01

Iovance's Amtagvi receives Health Canada approval for advanced melanoma

Health Canada issued NOC/c for Amtagvi (lifileucel) for unresectable/metastatic melanoma after anti-PD-1 and targeted therapy.
August 7, 2025, 7:59 PM ET earnings materiality 0.90 neutral item 2.02 item 5.02 item 9.01

Iovance reports Q2 2025 earnings: $60M revenue, appoints new CFO, extends cash runway into Q4 2026

Q2 2025 total product revenue $60.0M (Amtagvi $54.1M, Proleukin $5.9M), net loss $111.7M.
July 3, 2025, 7:59 PM ET leadership materiality 0.65 neutral item 5.02

Iovance CFO Bellemin departs effective June 30; SVP Finance Rosinack named interim CFO

CFO Jean-Marc Bellemin's resignation accelerated from July 10 to June 30, 2025 by mutual agreement.
June 13, 2025, 7:59 PM ET leadership materiality 0.65 negative item 5.02 ◈ executive_change

Iovance CFO Jean-Marc Bellemin resigns effective July 10, 2025

Jean-Marc Bellemin, CFO and principal financial & accounting officer, resigns effective July 10, 2025.
May 8, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Iovance Q1 2025 revenue $49.3M; FY2025 guidance revised to $250-300M

Q1 2025 product revenue $49.3M from Amtagvi ($43.6M) and Proleukin ($5.7M); net loss $116.2M ($0.36 diluted).
February 27, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Iovance Q4 2024 product revenue $73.7M; FY24 total $164.1M, achieving upper end of guidance

Full year 2024 product revenue of $164.1M, within $160-165M guidance; Amtagvi $103.6M, Proleukin $60.5M.
November 7, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Iovance Q3 product revenue $58.6M; net loss narrows to $0.28/shr; FY24 guidance reaffirmed

Q3 2024 product revenue $58.6M ($42.1M Amtagvi, $16.5M Proleukin); net loss $83.5M ($0.28/shr) vs $113.8M ($0.46/shr) YoY.
August 8, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Iovance posts Q2 product revenue $31.1M; guides FY24 $160-165M, FY25 $450-475M

Q2 net loss $97.1M ($0.34/shr) vs. $106.5M ($0.47) a year ago; revenue $31.1M from Amtagvi ($12.8M) and Proleukin ($18.3M).
June 28, 2024, 7:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

Iovance submits MAA to EMA for lifileucel in advanced melanoma; first of multiple global filings

MAA seeks approval for lifileucel after prior PD-1 and BRAF/MEK therapy; would be first approved TIL therapy in EU.
June 3, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Iovance reports $363M cash, 50+ ATCs onboard for Amtagvi; frontline melanoma data shows 65.2% ORR

Cash position of ~$363M as of 3/31/2024; 600+ employees and 50+ payers covering 200M+ lives have approved Amtagvi for at least one patient.
May 24, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Iovance reports 65% ORR, 30% complete response rate for lifileucel + pembro in frontline melanoma

Confirmed ORR of 65.2% (30.4% CR, 34.8% PR) in 23 evaluable frontline advanced melanoma patients.
May 9, 2024, 7:59 PM ET earnings materiality 0.78 positive item 2.02 item 9.01 ◈ Earnings Releases

Iovance reports Q1 net loss $113M; Amtagvi launch strong with 100+ patients enrolled across 40+ ATCs

Net loss $113.0M ($0.42 per share) vs $107.4M ($0.50) YoY; revenue $0.7M from Proleukin sales.
April 3, 2024, 7:59 PM ET litigation materiality 0.60 positive item 8.01 item 9.01

Iovance settles derivative suit over director compensation; $600k fee, option cancellations

Iovance cancels 12,796 (2019), 11,731 (2020), 8,603 (2021) options to non-employee directors; awards reduced below 75th peer percentile.
March 4, 2024, 6:59 PM ET regulatory materiality 0.85 positive item 8.01 item 9.01

FDA lifts clinical hold on Iovance's IOV-LUN-202 NSCLC trial; enrollment to resume

FDA cleared Iovance to resume patient enrollment in registrational IOV-LUN-202 trial for LN-145 TIL therapy in NSCLC.
February 29, 2024, 6:59 PM ET other material materiality 0.75 neutral item 8.01 item 9.01

Iovance reports $485M cash, AMTAGVI launch ongoing; partial clinical hold on lung TIL trial

Cash position ~$485M as of 2/22/24, including $197.1M from Feb 2024 equity offering.
February 28, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Iovance reports $444M net loss for 2023; Amtagvi approved and launched Feb 2024

FDA approved Amtagvi (lifileucel) on Feb 16, 2024 — first T cell therapy for a solid tumor (advanced melanoma).
February 22, 2024, 6:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Iovance closes $197.1M public offering of 23M shares at $9.15/share

Closed sale of 23,014,000 shares at $9.15 per share in underwritten offering.
February 20, 2024, 6:59 PM ET other material materiality 0.95 positive item 2.02 item 8.01 item 9.01

Iovance receives FDA accelerated approval for AMTAGVI (lifileucel) in advanced melanoma

AMTAGVI is first FDA-approved T cell therapy for a solid tumor cancer, indicated for advanced melanoma after anti-PD-1 and BRAF/MEK therapy.
February 20, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Iovance prices $211M common stock offering at $9.15/share

Issues 23,014,000 shares at $9.15; gross proceeds ~$211M, net ~$197.1M.
January 26, 2024, 6:59 PM ET regulatory materiality 0.75 negative item 8.01 item 9.01

Iovance discloses FDA clinical hold on NSCLC TIL trial; BLA for lifileucel in melanoma under review

FDA placed clinical hold on IOV-LUN-202 trial (NSCLC) on Dec 22, 2023; new enrollment paused.
January 8, 2024, 6:59 PM ET other material materiality 0.70 negative item 8.01 item 9.01

Iovance updates pipeline: BLA under review, NSCLC trial on hold

BLA for lifileucel in advanced melanoma under FDA review; pre-license inspection of iCTC facility completed in 2023.
December 27, 2023, 6:59 PM ET regulatory materiality 0.75 negative item 8.01 item 9.01

FDA places clinical hold on Iovance's LN-145 NSCLC trial after fatal adverse event

FDA placed clinical hold on IOV-LUN-202 on Dec 22, 2023, after a Grade 5 fatal SAE potentially linked to preconditioning.
November 7, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Iovance reports Q3 net loss of $113.8M; BLA for lifileucel on track with PDUFA Feb 24, 2024

Net loss of $113.8M ($0.46/share) vs $99.6M ($0.63/share) in Q3 2022; revenue of $0.5M from Proleukin acquisition.
September 15, 2023, 7:59 PM ET regulatory materiality 0.80 negative item 8.01 item 9.01

FDA extends PDUFA date for Iovance's lifileucel BLA to Feb 24, 2024 due to resource constraints

FDA extended PDUFA target action date for lifileucel BLA from prior to February 24, 2024, citing resource constraints.
August 18, 2023, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Iovance reports LN-145 + pembrolizumab 42.1% ORR in ICI-naïve mNSCLC trial

ORR of 42.1% in ICI-naïve mNSCLC; 80% in treatment-naïve, 42.9% post-chemo, 14.3% EGFR-mutated post-TKI.
August 8, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Iovance reports Q2 2023 net loss $106.5M, cash $317.3M; lifileucel PDUFA Nov 25

FDA set PDUFA date Nov 25, 2023 for lifileucel BLA in advanced melanoma under priority review.
July 13, 2023, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Iovance Biotherapeutics closes $172.5M public offering of 23M shares at $7.50/share

Closed underwritten public offering of 23,000,000 shares at $7.50 per share.
July 11, 2023, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

Iovance prices $150M public offering of 20M shares at $7.50; underwriter option for 3M more

Priced 20M shares at $7.50/share for gross proceeds of $150M; net proceeds ~$140.2M.
July 10, 2023, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Iovance gets FDA positive feedback for TIL therapy in NSCLC; 26.1% ORR in 23 patients

FDA Type B meeting supports IOV-LUN-202 trial design for accelerated approval of LN-145 in post-anti-PD-1 advanced NSCLC.
June 16, 2023, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 1.02 item 9.01 ◈ Material Agreements ×2

Iovance enters $450M ATM equity offering with Jefferies, replaces prior program

Company entered new Open Market Sale Agreement with Jefferies for up to $450M in at-the-market common stock sales.